No insider purchase over the last 90 days. The latest, by 조봉호, was filed 16 Jul 2026.
REMEDI Inc.: what insiders have been doing
REMEDI Inc., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). Over the twelve months to 6 November 2026, 5 filings were filed, from 5 insiders.
Not one open-market sale was filed. On the buying side, 5 insiders reported 5 purchases. The totals exclude 5 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 2 senior executives, 1 major shareholder and 1 board member among the declarants.
The clock since the last published purchase (16 July 2026) now reads 117 days.
Compared with its exchange (2,657 companies, median 7 filings), a count of 5 filings is below the norm. Over the whole record (from 2026), the tally stands at 5 purchases and no sales.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and Vetoquinol SA. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleTransparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- 25,575 sharesShareKRXDART:20260716000309Canonical exit: 14 Oct 2026 (T+90)
- 1,600 sharesShareKRXDART:20260716000681Canonical exit: 14 Oct 2026 (T+90)
- 240 sharesShareKRXDART:20260715000292Canonical exit: 13 Oct 2026 (T+90)
- 940 sharesShareKRXDART:20260715000230Canonical exit: 13 Oct 2026 (T+90)
- 168,224 sharesKRXDART:20260714000136Canonical exit: 12 Oct 2026 (T+90)
6 of 6 declarations
About REMEDI Inc.
레메디 is a company listed on the XKRX market. It specializes in the health and biotechnology sector.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
